<div id="readability-page-1"><p>LifeSci Capital analyst Oliver McCammon maintained a Buy rating on Corbus Pharmaceuticals today and set a price target of $38.00.</p><h3>Claim 55% Off TipRanks</h3><ul><li>Unlock  hedge fund-level data  and  powerful investing tools  for smarter, sharper decisions  </li><li> Discover top-performing stock ideas and upgrade to a portfolio of market leaders with  Smart Investor Picks  </li></ul> <p>According to TipRanks, McCammon is a 5-star analyst with an average return of <span>88.0%</span> and a 64.91% success rate. McCammon covers the Healthcare sector, focusing on stocks such as Perspective Therapeutics, Celcuity, and Corbus Pharmaceuticals.</p> <p>The word on The Street in general, suggests a Strong Buy analyst consensus rating for Corbus Pharmaceuticals with a $40.78 average price target.</p></div>

CRBP

IBBQ

LABU

SBIO

<p>LifeSci Capital analyst Oliver McCammon has maintained a Buy rating on Corbus Pharmaceuticals (CRBP) with a price target of $38.00. McCammon, a 5-star analyst, has an average return of 88.0% and a 64.91% success rate. The overall analyst consensus for Corbus Pharmaceuticals is a Strong Buy, with an average price target of $40.78.</p>

Tip Ranks

Corbus Pharma

SPDR S&P Biotech

Invesco Nasdaq Biotechnology ETF

Direxion S&P Biotech Bull 3X

iShares Biotechnology ETF

Invesco Biotechnology & Genome ETF

First Trust NYSE Arca Biotech Index Fd

VanEck Biotech ETF

ALPS Medical Breakthrough

Proshares Ultra Nasdaq Biotech

Perspective Therapeutics

Celcuity

Corbus Pharmaceuticals (CRBP) Receives a Buy from LifeSci Capital